Company
THAT +1.11%Thalia Therapeutics Plc
Market Cap: £8.2 Million
GBP as of Aug 2, 2026 | US$11.0 Million
$THAT +1.11% $THAT United Kingdom Healthcare Biotechnology UK Healthcare UK BiotechnologyCompany Description
Thalia Therapeutics Plc is a biotechnology company developing RNA-based therapeutics and delivery technologies for oncology and cardiovascular disease. The company's proprietary Nuvec delivery system uses amorphous silica nanoparticles with an irregular surface structure designed to trap, protect, and deliver RNA molecules intracellularly. This silica-based platform can be functionalized with proteins, peptides, antibodies, or radionuclides for targeted therapeutic applications. Additionally, Thalia Therapeutics develops LipTide, a lipid and peptide-based delivery system that mimics natural virus mechanisms for efficient cellular RNA delivery. The company maintains a growing pipeline of RNA-based programs focusing on dual-target cardiovascular treatments, including a novel long-duration siRNA program targeting PCSK9 and lipoprotein. Thalia Therapeutics addresses key limitations in existing nucleic acid delivery systems, offering potential applications across gene therapy, cancer therapeutics, and vaccine development. The company operates as a pre-clinical stage specialist pharmaceutical enterprise, making its technologies available for licensing to pharmaceutical and biotech partners.
Thalia Therapeutics Plc Market Capitalization Over Time
View HistoryEvolution of Thalia Therapeutics Plc market cap in the past 5 years
Market capitalizations are calculated from the opening stock price at the beginning of each month.
Top Competitors by Market Capitalization
Industry: Biotechnology
| Company | Market Cap (USD) |
|---|---|
| Novo Nordisk | $209.25 B |
| Vertex Pharmaceuticals | $121.09 B |
| Regeneron Pharmaceuticals | $78.52 B |
| argenx | $52.93 B |
| Beigene Ltd. | $51.33 B |
Sector: Healthcare
| Company | Market Cap (USD) |
|---|---|
| Lilly | $1.024 T |
| Johnson & Johnson | $617.78 B |
| AbbVie | $443.36 B |
| Roche | $418.93 B |
| UnitedHealth Group | $376.34 B |
Detailed Description
Thalia Therapeutics Plc is a biotechnology company developing RNA-based therapeutics and delivery technologies for oncology and cardiovascular disease. The company's proprietary Nuvec delivery system uses amorphous silica nanoparticles with an irregular surface structure designed to trap, protect, and deliver RNA molecules intracellularly. This silica-based platform can be functionalized with proteins, peptides, antibodies, or radionuclides for targeted therapeutic applications. Additionally, Thalia Therapeutics develops LipTide, a lipid and peptide-based delivery system that mimics natural virus mechanisms for efficient cellular RNA delivery. The company maintains a growing pipeline of RNA-based programs focusing on dual-target cardiovascular treatments, including a novel long-duration siRNA program targeting PCSK9 and lipoprotein. Thalia Therapeutics addresses key limitations in existing nucleic acid delivery systems, offering potential applications across gene therapy, cancer therapeutics, and vaccine development. The company operates as a pre-clinical stage specialist pharmaceutical enterprise, making its technologies available for licensing to pharmaceutical and biotech partners.
Financials
| Last Financial Reports Date | Dec. 31, 2025 |
| Revenue TTM | £7,264 |
| EBITDA | £0 |
| Gross Profit TTM | £7,264 |
| Profit Margin | 0.00% |
| Operating Margin | -19446.17% |
| Quarterly Revenue Growth | 5.90% |
Stocks & Indexes
Thalia Therapeutics Plc main stocks and indexes inclusions.
$THATFTSE AIM All-Share